In one, a 7-year-old girl with giant CMN with an AKAP9-BRAF fusion mutation had a significant improvement in the thickness, rugosity, and nodularity of her lesion after six months on 0.5 mg of trametinib daily; however, the lesion did not lighten or shrink [122]. The gene discussed is BRAF; the disease is congenital mesoblastic nephroma.